Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer

Inclusion Criteria

• •1. Histologically confirmed adenocarcinoma of the prostate
• •2. High risk localized adenocarcinoma defined by at least one of the following criteria:
• •* Clinical stage T2c, T3 or T4
• •* Gleason score ≥ 8
• •* Prostate-specific antigen (PSA)≥ 20 ng/ml and ≤ 100 ng/ml
• •3. Patient cN0, pN0 or Nx (negative lymphadenectomy or no lymphadenectomy)
• •4. No pelvic adenopathy ≥ 15 mm on CT or MRI,
• •5. Absence of bone and/or visceral metastasis
• •6. Androgen deprivation beginning no later than the day of radiotherapy and up to six months before irradiation
• •7. Absence of prior pelvic radiotherapy,
• •8. Absence of surgical treatment of prostate cancer except transurethral resection performed within 4 months minimum before radiotherapy,
• •9. Age ≥ 18 years and ≤ 85 years
• •10. ECOG performance status ≤ 1,
• •11. Estimated life expectancy \> 5 years
• •12. Membership of a social security system,
• •13. Signed informed consent.